France· FR:66422290
MIFEGYNE 200 mg, comprimé
A mifepristone product containing mifépristone, registered in France by EXELGYN. The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Mifepristone is registered in 14 of 19 countries.
Countries holding a registration under ATC G03XB01 (mifepristone), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Mifepristone · ATC G03XB01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of mifepristone costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mifepristone · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$53.60
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MIFÉPRISTONE
- Manufacturer
- EXELGYN
- Country
- France (FR)
- ATC code
- G03XB01
- ATC class
- Mifepristone
- Defined daily dose
- 0.2 g, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009365134713 plaquette(s) PVC-Aluminium de 1 comprimé(s)
- cip13340095821061730 plaquette(s) PVC-Aluminium de 1 comprimé(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
378 interactions on record for mifepristone.
Graded by severity as the source publishes them — 209 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mifepristone · interactions on record
378 records
- 209 severe
- 161 moderate
- 8 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mifepristone in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsMifegyne 200 mg, tablettenEuro Registratie Collectief B.V.
- FinlandMifegyneParanova Oy
- United StatesMifepristoneEvita Solutions LLC
- CzechiaMIFEGYNEExelgyn, Paris
- United KingdomMifegyne 200mg tabletsNordic Pharma Ltd
- SpainMIFEGYNE 200 mg COMPRIMIDOSExelgyn
- SwedenMifegyne 200 mg TablettExelgyn, Paris
- IrelandMifegyne 200 mg tabletsEXELGYN
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Mifegyne
- Belgium · Mifegyne
- Bulgaria · Мифегин
- Cyprus · Mifegyne
- Czechia · Mifegyne
- Germany · Mifegyne
- Denmark · Mifegyne
- Estonia · Mifegyne
- Spain · Mifegyne
- Finland · Mifegyne
- United Kingdom (Northern Ireland) · Mifegyne, Mifepristone Linepharma
- Greece · Mifegyne
- Croatia · Mifegyne
- Ireland · Mifegyne
- Iceland · Mifegyne
- Italy · Mifegyne
- Lithuania · Mifegyne
- Luxembourg · Mifegyne
- Latvia · Mifegyne
- Netherlands · Mifegyne
- Norway · Mifegyne
- Portugal · Mifegyne
- Romania · Mifegyne
- Sweden · Mifegyne, Mifepristone Nordic
- Slovenia · Mifegyne
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/df3034fd-e4e0-4159-b548-ce466ece7fc0 GET /v1/drugs/df3034fd-e4e0-4159-b548-ce466ece7fc0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66422290",
"date_amm": "1988-12-28",
"type_amm": "Procédure de reconnaissance mutuelle",
"numero_ue": null,
"substance": "MIFÉPRISTONE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about mifepristone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.